Navigation Links
BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
Date:11/5/2013

JERUSALEM, Nov. 5, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Thursday, November 21, 2013 in New York City beginning at 8:15 am EST.

(Logo:  http://photos.prnewswire.com/prnh/20130730/630769 )

The event will feature presentations from members of BioLineRx's senior management team, including a unique perspective on the current state of the biotechnology market and industry trends by recently appointed BioLineRx Director, Dr. BJ Bormann, most recently Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer Ingelheim Pharmaceuticals Inc., and former Vice President, Strategic Alliances, at Pfizer.

Selected key opinion leaders will be speaking in reference to several programs within BioLineRx's pipeline, including:

  • BL-8040 (for treatment of AML and other hematological cancers) - Dr. Martin Tallman, of Sloan-Kettering Memorial Cancer Center, will provide insight on the current AML and hematological oncology space and the market for potential breakthrough products such as BL-8040
  • BL-5010 (for treatment of skin lesions) - Dr. Miri Seiberg, a world-renowned independent dermatology expert, will be providing insight on the current need for new skin lesion therapies and the relevant market potential for such therapies
  • BL-7010 (for treatment of celiac disease) - Dr. Joseph A. Murray, a leading celiac disease researcher at the Mayo Clinic, will discuss the current state of the celiac market and enormous need for breakthrough celiac treatments

The presentations will begin at 9:00 am EST and conclude at approximately 11:45 am EST. A recording of the presentations will be available after the event, through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and at www.kcsa.com.

Analysts and qualified investors who would like to register or learn more about the event should contact Diane Imas of KCSA Strategic Communications at (212) 896-1242 or dimas@kcsa.com. Registration is required as space is limited.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contacts:
Garth Russell / Todd Fromer
KCSA Strategic Communications
1 212-896-1250 / 1 212-896-1215
grussell@kcsa.com / tfromer@kcsa.com

or

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipih@netvision.net.il

 


'/>"/>
SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
2. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
3. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
5. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx to Present at 15th International Celiac Disease Symposium
8. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
9. BioLineRx Appoints B. J. Bormann to Board of Directors
10. BioLineRx Reports Second Quarter 2013 Results
11. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):